CDT Equity Inc. (CDT) 10-Year Financial Performance & Capital Metrics

CDT • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutCDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.Show more

Revenue $0
EBITDA -$15M -590.1%
Net Income -$18M -3227.5%
EPS (Diluted) -20.53 -470.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -10.24 +58.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 21.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-48.91%

EPS CAGR

10Y-

5Y-

3Y-

TTM-3880.43%

ROCE

10Y Avg-8114.65%

5Y Avg-8114.65%

3Y Avg-840.58%

Latest-

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	457K
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	-457K
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	3.17M	3.16M	5.26M	14.96M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	2.89M	3.05M	5.17M	11.58M
SG&A % of Revenue	-	-	-	-
Research & Development	283K	111K	90K	3.38M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	0	0
Operating Income+	-3.17M	-3.16M	-5.26M	-15.42M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	0%	-0.67%	-1.93%
EBITDA+	-3.17M	-4.89M	3.05M	-14.96M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	-0.54%	1.62%	-5.9%
D&A (Non-Cash Add-back)	0	0	0	457K
EBIT	-3.17M	-4.89M	3.05M	-16.3M
Net Interest Income+	0	1.98M	-196K	-1.49M
Interest Income	0	1.98M	15K	13K
Interest Expense	0	0	211K	1.51M
Other Income/Expense	-484K	-1.73M	8.1M	-2.38M
Pretax Income+	-3.66M	-4.89M	2.84M	-17.8M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	-0.19%	1%
Net Income+	-3.66M	-4.89M	-535K	-17.8M
Net Margin %	-	-	-	-
Net Income Growth %	-	-0.34%	0.89%	-32.27%
Net Income (Continuing)	-3.66M	-4.89M	2.84M	-17.8M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-1.01	-0.07	-3.60	-20.53
EPS Growth %	-	0.93%	-52.33%	-4.7%
EPS (Basic)	-1.01	-0.07	-3.60	-20.53
Diluted Shares Outstanding	576	3.62M	1.7M	2.06M
Basic Shares Outstanding	576	3.62M	1.67M	2.03M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	104.16K	0	5.73M	2.71M
Cash & Short-Term Investments	48.55K	0	4.23M	554K
Cash Only	48.55K	0	4.23M	554K
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	489K
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	0	0	0
Total Non-Current Assets+	108.96K	5K	1.49M	1.48M
Property, Plant & Equipment	0	0	0	303K
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	1.02B
Intangible Assets	0	5K	0	419.07M
Long-Term Investments	0	0	0	0
Other Non-Current Assets	108.96K	0	1.49M	-1.44B
Total Assets+	213.13K	5K	7.22M	4.19M
Asset Turnover	-	-	-	-
Asset Growth %	-	-0.98%	1443.8%	-0.42%
Total Current Liabilities+	192.51K	4.18M	1.8M	10.74M
Accounts Payable	0	0	215K	1.43M
Days Payables Outstanding	-	-	-	1.14K
Short-Term Debt	177.06K	175K	985K	7.35M
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	15.45K	3.29M	0	0
Current Ratio	0.54x	-	3.18x	0.25x
Quick Ratio	0.54x	-	3.18x	0.25x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	0	5.92M	5.88M	245K
Long-Term Debt	0	1.83M	0	0
Capital Lease Obligations	0	0	0	107K
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	-545.75K	5.88M	138K
Total Liabilities	192.51K	10.09M	7.68M	10.99M
Total Debt+	177.06K	2.01M	985K	7.46M
Net Debt	128.5K	2.01M	-3.24M	6.9M
Debt / Equity	8.59x	-	-	-
Debt / EBITDA	-	-	0.32x	-
Net Debt / EBITDA	-	-	-1.06x	-
Interest Coverage	-	-	-24.94x	-10.24x
Total Equity+	20.62K	-10.09M	-457K	-6.79M
Equity Growth %	-	-490.31%	0.95%	-13.86%
Book Value per Share	35.79	-2.79	-0.27	-3.29
Total Shareholders' Equity	20.62K	-10.09M	-457K	-6.79M
Common Stock	331	6K	7K	14K
Retained Earnings	-4.38K	-10.77M	-11.3M	-29.1M
Treasury Stock	0	0	0	0
Accumulated OCI	0	675K	411K	414K
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.15M	-2.27M	-7.72M	-9.68M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-0.05%	-2.41%	-0.25%
Net Income	-3.66M	-4.89M	-535K	-17.8M
Depreciation & Amortization	0	0	0	457K
Stock-Based Compensation	0	0	199K	1.63M
Deferred Taxes	0	0	0	0
Other Non-Cash Items	149K	2.02M	-4.87M	6.17M
Working Capital Changes	1.36M	596K	-2.52M	-142K
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	0	0	215K	1.23M
Cash from Investing+	0	-183K	725K	-43K
Capital Expenditures	0	0	0	-51K
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	-331K	228K	0
Cash from Financing+	1.9M	2.45M	10.93M	6.07M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	0	8.64M	289K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-2.15M	-2.27M	-7.72M	-9.73M
FCF Margin %	-	-	-	-
FCF Growth %	-	-0.05%	-2.41%	-0.26%
FCF per Share	-3733.40	-0.63	-4.55	-4.71
FCF Conversion (FCF/Net Income)	0.59x	0.46x	14.44x	0.54x
Interest Paid	0	0	124K	80K
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-17736.07%	-	-	-
Debt / Equity	8.59x	-	-	-
Interest Coverage	-	-	-24.94x	-10.24x
FCF Conversion	0.59x	0.46x	14.44x	0.54x

Revenue by Segment

	2024
Automation Solutions	1.32B
Automation Solutions Growth	-

Revenue by Geography

	2024
UNITED STATES	1.39B
UNITED STATES Growth	-
Other Countries	698.34M
Other Countries Growth	-
CANADA	160.01M
CANADA Growth	-
GERMANY	118.26M
GERMANY Growth	-
CHINA	92.11M
CHINA Growth	-

Frequently Asked Questions

Growth & Financials

CDT Equity Inc. (CDT) grew revenue by 0.0% over the past year. Growth has been modest.

CDT Equity Inc. (CDT) reported a net loss of $20.3M for fiscal year 2024.

Dividend & Returns

CDT Equity Inc. (CDT) generated $34.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

← Back to Screener